IN2015DN01480A - - Google Patents
Info
- Publication number
- IN2015DN01480A IN2015DN01480A IN1480DEN2015A IN2015DN01480A IN 2015DN01480 A IN2015DN01480 A IN 2015DN01480A IN 1480DEN2015 A IN1480DEN2015 A IN 1480DEN2015A IN 2015DN01480 A IN2015DN01480 A IN 2015DN01480A
- Authority
- IN
- India
- Prior art keywords
- compositions
- methods
- genetic disease
- genetic
- disease
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/795—Porphyrin- or corrin-ring-containing peptides
- C07K14/805—Haemoglobins; Myoglobins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/52—Genes encoding for enzymes or proenzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
- C12N2510/02—Cells for production
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Toxicology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Enzymes And Modification Thereof (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261694693P | 2012-08-29 | 2012-08-29 | |
PCT/US2013/057214 WO2014036219A2 (en) | 2012-08-29 | 2013-08-29 | Methods and compositions for treatment of a genetic condition |
Publications (1)
Publication Number | Publication Date |
---|---|
IN2015DN01480A true IN2015DN01480A (tr) | 2015-07-03 |
Family
ID=50184630
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IN1480DEN2015 IN2015DN01480A (tr) | 2012-08-29 | 2013-08-29 |
Country Status (27)
Country | Link |
---|---|
US (4) | US9650648B2 (tr) |
EP (1) | EP2890780B8 (tr) |
JP (4) | JP2015533786A (tr) |
KR (3) | KR102218562B1 (tr) |
CN (1) | CN104704110B (tr) |
AU (1) | AU2013308770B2 (tr) |
CA (2) | CA3171494A1 (tr) |
CL (1) | CL2015000450A1 (tr) |
DK (1) | DK2890780T3 (tr) |
EA (1) | EA039384B1 (tr) |
ES (1) | ES2812599T3 (tr) |
HK (1) | HK1210502A1 (tr) |
HR (1) | HRP20201443T1 (tr) |
HU (1) | HUE050516T2 (tr) |
IL (1) | IL237050B (tr) |
IN (1) | IN2015DN01480A (tr) |
LT (1) | LT2890780T (tr) |
MX (1) | MX367081B (tr) |
PH (2) | PH12015500433A1 (tr) |
PL (1) | PL2890780T3 (tr) |
PT (1) | PT2890780T (tr) |
RS (1) | RS60838B1 (tr) |
SG (2) | SG10201701601WA (tr) |
SI (1) | SI2890780T1 (tr) |
UA (1) | UA118957C2 (tr) |
WO (1) | WO2014036219A2 (tr) |
ZA (1) | ZA201500900B (tr) |
Families Citing this family (103)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2853829C (en) | 2011-07-22 | 2023-09-26 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
GB201122458D0 (en) | 2011-12-30 | 2012-02-08 | Univ Wageningen | Modified cascade ribonucleoproteins and uses thereof |
BR112014020625A2 (pt) | 2012-02-24 | 2017-07-04 | Hutchinson Fred Cancer Res | polinucleotídeo, polipeptídeo, composição, célula e célula tronco editada por genoma |
MX362866B (es) | 2012-05-25 | 2019-02-20 | Univ California | Metodos y composiciones para la modificacion de adn objetivo dirigida por arn y para la modulacion de la transcripcion dirigida por arn. |
EP3372679A1 (en) * | 2012-10-23 | 2018-09-12 | Toolgen Incorporated | Composition for cleaving a target dna comprising a guide rna specific for the target dna and cas protein-encoding nucleic acid or cas protein, and use thereof |
PT3138910T (pt) | 2012-12-06 | 2017-10-18 | Sigma Aldrich Co Llc | Modificação e regulação de genoma baseado em crispr |
WO2014130955A1 (en) | 2013-02-25 | 2014-08-28 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
JP2016519652A (ja) | 2013-03-14 | 2016-07-07 | カリブー・バイオサイエンシーズ・インコーポレイテッド | 核酸ターゲティング核酸の組成物および方法 |
JP2016522679A (ja) | 2013-04-04 | 2016-08-04 | プレジデント アンド フェローズ オブ ハーバード カレッジ | CRISPR/Cas系を用いたゲノム編集の治療的使用 |
US9873894B2 (en) * | 2013-05-15 | 2018-01-23 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
EP4389903A2 (en) * | 2013-06-05 | 2024-06-26 | Duke University | Rna-guided gene editing and gene regulation |
JP2016528890A (ja) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | CRISPR/Cas系を用いるゲノム編集の治療用の使用 |
US20150044192A1 (en) | 2013-08-09 | 2015-02-12 | President And Fellows Of Harvard College | Methods for identifying a target site of a cas9 nuclease |
US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
AU2014312295C1 (en) * | 2013-08-28 | 2020-08-13 | Sangamo Therapeutics, Inc. | Compositions for linking DNA-binding domains and cleavage domains |
US9388430B2 (en) | 2013-09-06 | 2016-07-12 | President And Fellows Of Harvard College | Cas9-recombinase fusion proteins and uses thereof |
US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
US9340800B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | Extended DNA-sensing GRNAS |
KR102380245B1 (ko) | 2013-11-07 | 2022-03-30 | 에디타스 메디신, 인코포레이티드 | 지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물 |
EP3492593B1 (en) * | 2013-11-13 | 2021-08-18 | Children's Medical Center Corporation | Nuclease-mediated regulation of gene expression |
US20150166982A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting pi3k point mutations |
HUE051232T2 (hu) * | 2014-02-03 | 2021-03-01 | Sangamo Therapeutics Inc | Béta-talasszémia kezelésére szolgáló eljárások és készítmények |
AU2015218576B2 (en) | 2014-02-24 | 2020-02-27 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated targeted integration |
WO2015134812A1 (en) | 2014-03-05 | 2015-09-11 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating usher syndrome and retinitis pigmentosa |
US11141493B2 (en) | 2014-03-10 | 2021-10-12 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
US11339437B2 (en) | 2014-03-10 | 2022-05-24 | Editas Medicine, Inc. | Compositions and methods for treating CEP290-associated disease |
EP3553176A1 (en) | 2014-03-10 | 2019-10-16 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating leber's congenital amaurosis 10 (lca10) |
CA2942762C (en) | 2014-03-18 | 2023-10-17 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of zinc finger protein expression |
JP2017511132A (ja) * | 2014-03-26 | 2017-04-20 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドThe Brigham and Women’s Hospital, Inc. | ヒト造血幹/前駆細胞のエクスビボ拡大のための組成物および方法 |
EP3981876A1 (en) * | 2014-03-26 | 2022-04-13 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating sickle cell disease |
WO2015148860A1 (en) * | 2014-03-26 | 2015-10-01 | Editas Medicine, Inc. | Crispr/cas-related methods and compositions for treating beta-thalassemia |
US10077453B2 (en) | 2014-07-30 | 2018-09-18 | President And Fellows Of Harvard College | CAS9 proteins including ligand-dependent inteins |
EP3186376B1 (en) | 2014-08-27 | 2019-03-20 | Caribou Biosciences, Inc. | Methods for increasing cas9-mediated engineering efficiency |
HUE055583T2 (hu) * | 2014-09-16 | 2021-12-28 | Sangamo Therapeutics Inc | Eljárások és készítmények nukleáz által közvetített genommódosításhoz és -javításhoz hematopoetikus õssejtekben |
JP2017536826A (ja) * | 2014-11-24 | 2017-12-14 | チルドレンズ メディカル センター コーポレーション | 幹細胞および/または前駆細胞からの赤血球産生を改善するためのsh2b3の調節 |
WO2016094880A1 (en) * | 2014-12-12 | 2016-06-16 | The Broad Institute Inc. | Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs) |
EP3262173A2 (en) | 2015-02-23 | 2018-01-03 | Crispr Therapeutics AG | Materials and methods for treatment of human genetic diseases including hemoglobinopathies |
CN107532182A (zh) | 2015-02-23 | 2018-01-02 | 克里斯珀医疗股份公司 | 治疗血红蛋白病的材料和方法 |
WO2016168371A1 (en) * | 2015-04-13 | 2016-10-20 | Invitae Corporation | Methods, systems and processes of identifying genetic variation in highly similar genes |
EP3286571B1 (en) | 2015-04-24 | 2021-08-18 | Editas Medicine, Inc. | Evaluation of cas9 molecule/guide rna molecule complexes |
US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
WO2016183298A2 (en) | 2015-05-12 | 2016-11-17 | Sangamo Biosciences, Inc. | Nuclease-mediated regulation of gene expression |
US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
WO2017015637A1 (en) * | 2015-07-22 | 2017-01-26 | Duke University | High-throughput screening of regulatory element function with epigenome editing technologies |
US10435441B2 (en) * | 2015-09-23 | 2019-10-08 | Sangamo Therapeutics, Inc. | HTT repressors and uses thereof |
BR112018008109A2 (pt) * | 2015-10-20 | 2018-11-06 | Pioneer Hi Bred Int | métodos para modificar uma sequência de nucleotídeos no genoma de uma célula vegetal, produzir uma planta, produzir tecido de calo de planta que tem uma sequência de nucleotídeos modificada em seu genoma sem o uso de um marcador selecionável, e planta de progênie da planta |
EP4269577A3 (en) | 2015-10-23 | 2024-01-17 | President and Fellows of Harvard College | Nucleobase editors and uses thereof |
AU2016343887B2 (en) | 2015-10-28 | 2023-04-06 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
US20180273609A1 (en) | 2015-11-04 | 2018-09-27 | Crispr Therapeutics Ag | Materials and methods for treatment of hemoglobinopathies |
EP4036228A1 (en) | 2015-11-13 | 2022-08-03 | Avellino Lab USA, Inc. | Methods for the treatment of corneal dystrophies |
IL297018A (en) * | 2015-12-18 | 2022-12-01 | Sangamo Therapeutics Inc | Directed cleavage of cell mhc receptor |
EP3417061B1 (en) | 2016-02-18 | 2022-10-26 | The Regents of the University of California | Methods and compositions for gene editing in stem cells |
CN109153994A (zh) * | 2016-03-14 | 2019-01-04 | 爱迪塔斯医药公司 | 用于治疗β-血红蛋白病的CRISPR/CAS相关方法和组合物 |
US11512311B2 (en) | 2016-03-25 | 2022-11-29 | Editas Medicine, Inc. | Systems and methods for treating alpha 1-antitrypsin (A1AT) deficiency |
EP3494220A1 (en) | 2016-08-02 | 2019-06-12 | Editas Medicine, Inc. | Compositions and methods for treating cep290 associated disease |
SG11201900907YA (en) | 2016-08-03 | 2019-02-27 | Harvard College | Adenosine nucleobase editors and uses thereof |
WO2018031683A1 (en) | 2016-08-09 | 2018-02-15 | President And Fellows Of Harvard College | Programmable cas9-recombinase fusion proteins and uses thereof |
WO2020225754A1 (en) | 2019-05-06 | 2020-11-12 | Mcmullen Tara | Crispr gene editing for autosomal dominant diseases |
CN109963945A (zh) | 2016-08-20 | 2019-07-02 | 阿维利诺美国实验室股份有限公司 | 单一向导rna、crispr/cas9系统及其使用方法 |
MY193234A (en) * | 2016-08-24 | 2022-09-27 | Sangamo Therapeutics Inc | Regulation of gene expression using engineered nucleases |
SG10201913948PA (en) | 2016-08-24 | 2020-03-30 | Sangamo Therapeutics Inc | Engineered target specific nucleases |
US11542509B2 (en) | 2016-08-24 | 2023-01-03 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
US10960085B2 (en) | 2016-09-07 | 2021-03-30 | Sangamo Therapeutics, Inc. | Modulation of liver genes |
US20190330620A1 (en) * | 2016-10-14 | 2019-10-31 | Emendobio Inc. | Rna compositions for genome editing |
CN110214180A (zh) | 2016-10-14 | 2019-09-06 | 哈佛大学的校长及成员们 | 核碱基编辑器的aav递送 |
US10745677B2 (en) | 2016-12-23 | 2020-08-18 | President And Fellows Of Harvard College | Editing of CCR5 receptor gene to protect against HIV infection |
TWI829101B (zh) * | 2017-01-09 | 2024-01-11 | 美商聖加莫治療股份有限公司 | 使用經工程改造之核酸酶調控基因表現 |
TW201839136A (zh) | 2017-02-06 | 2018-11-01 | 瑞士商諾華公司 | 治療血色素異常症之組合物及方法 |
EP3592853A1 (en) | 2017-03-09 | 2020-01-15 | President and Fellows of Harvard College | Suppression of pain by gene editing |
EP3592777A1 (en) | 2017-03-10 | 2020-01-15 | President and Fellows of Harvard College | Cytosine to guanine base editor |
EP3596217A1 (en) | 2017-03-14 | 2020-01-22 | Editas Medicine, Inc. | Systems and methods for the treatment of hemoglobinopathies |
CN110914426A (zh) | 2017-03-23 | 2020-03-24 | 哈佛大学的校长及成员们 | 包含核酸可编程dna结合蛋白的核碱基编辑器 |
WO2018200597A1 (en) * | 2017-04-24 | 2018-11-01 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Homology directed repair compositions for the treatment of hemoglobinopathies |
EP3622070A2 (en) | 2017-05-10 | 2020-03-18 | Editas Medicine, Inc. | Crispr/rna-guided nuclease systems and methods |
WO2018209320A1 (en) | 2017-05-12 | 2018-11-15 | President And Fellows Of Harvard College | Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation |
BR112020001059A2 (pt) | 2017-07-18 | 2020-07-14 | Calimmune, Inc. | composições e métodos para o tratamento de beta-hemoglobinopatias |
WO2019023680A1 (en) | 2017-07-28 | 2019-01-31 | President And Fellows Of Harvard College | METHODS AND COMPOSITIONS FOR EVOLUTION OF BASIC EDITORS USING PHAGE-ASSISTED CONTINUOUS EVOLUTION (PACE) |
US11319532B2 (en) | 2017-08-30 | 2022-05-03 | President And Fellows Of Harvard College | High efficiency base editors comprising Gam |
JP2021500036A (ja) | 2017-10-16 | 2021-01-07 | ザ ブロード インスティテュート, インコーポレーテッドThe Broad Institute, Inc. | アデノシン塩基編集因子の使用 |
WO2019081982A1 (en) | 2017-10-26 | 2019-05-02 | Crispr Therapeutics Ag | SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES |
EP3511412A1 (en) | 2018-01-12 | 2019-07-17 | Genethon | Genetically engineered hematopoietic stem cell as a platform for systemic protein expression |
US11268077B2 (en) | 2018-02-05 | 2022-03-08 | Vertex Pharmaceuticals Incorporated | Materials and methods for treatment of hemoglobinopathies |
CN111954540A (zh) * | 2018-02-08 | 2020-11-17 | 桑格摩生物治疗股份有限公司 | 工程化靶标特异性核酸酶 |
KR20200123201A (ko) | 2018-02-21 | 2020-10-28 | 알시온 라이프사이언스 인크. | 유체 전달 시스템 및 방법 |
EP3843826A4 (en) | 2018-08-27 | 2022-09-14 | Alcyone Therapeutics, Inc. | FLUID DELIVERY SYSTEMS AND METHODS |
BR112021018607A2 (pt) | 2019-03-19 | 2021-11-23 | Massachusetts Inst Technology | Métodos e composições para editar sequências de nucleotídeos |
US20200316116A1 (en) | 2019-04-02 | 2020-10-08 | Sangamo Therapeutics, Inc. | Method for the treatment of beta-thalassemia |
WO2020208223A1 (en) * | 2019-04-12 | 2020-10-15 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Correction of βeta-thalassemia phenotype by genetically engineered hematopoietic stem cell |
CN112391410B (zh) * | 2020-02-17 | 2024-04-02 | 华东师范大学 | 一种sgRNA及其在修复内含子异常剪接中的应用 |
WO2021022189A1 (en) * | 2019-08-01 | 2021-02-04 | The Regents Of The University Of California | Compositions and methods for treating alpha thalassemia |
WO2021026336A2 (en) * | 2019-08-07 | 2021-02-11 | I Altius Institute For Biomedical Sciences | Compositions and methods for modulation of gene expression |
WO2021216622A1 (en) | 2020-04-21 | 2021-10-28 | Aspen Neuroscience, Inc. | Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom |
US20230165909A1 (en) | 2020-04-21 | 2023-06-01 | Aspen Neuroscience, Inc. | Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom |
CN116096873A (zh) | 2020-05-08 | 2023-05-09 | 布罗德研究所股份有限公司 | 同时编辑靶标双链核苷酸序列的两条链的方法和组合物 |
WO2023115041A1 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae attachment glycoproteins |
WO2023115039A2 (en) | 2021-12-17 | 2023-06-22 | Sana Biotechnology, Inc. | Modified paramyxoviridae fusion glycoproteins |
WO2023133595A2 (en) | 2022-01-10 | 2023-07-13 | Sana Biotechnology, Inc. | Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2023150518A1 (en) | 2022-02-01 | 2023-08-10 | Sana Biotechnology, Inc. | Cd3-targeted lentiviral vectors and uses thereof |
WO2023150647A1 (en) | 2022-02-02 | 2023-08-10 | Sana Biotechnology, Inc. | Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses |
WO2024044655A1 (en) | 2022-08-24 | 2024-02-29 | Sana Biotechnology, Inc. | Delivery of heterologous proteins |
WO2024064838A1 (en) | 2022-09-21 | 2024-03-28 | Sana Biotechnology, Inc. | Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof |
WO2024081820A1 (en) | 2022-10-13 | 2024-04-18 | Sana Biotechnology, Inc. | Viral particles targeting hematopoietic stem cells |
WO2024119157A1 (en) | 2022-12-02 | 2024-06-06 | Sana Biotechnology, Inc. | Lipid particles with cofusogens and methods of producing and using the same |
Family Cites Families (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US789538A (en) | 1904-11-11 | 1905-05-09 | Colin E Ham | Dumb-bell. |
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
US4186183A (en) | 1978-03-29 | 1980-01-29 | The United States Of America As Represented By The Secretary Of The Army | Liposome carriers in chemotherapy of leishmaniasis |
US4261975A (en) | 1979-09-19 | 1981-04-14 | Merck & Co., Inc. | Viral liposome particle |
US4485054A (en) | 1982-10-04 | 1984-11-27 | Lipoderm Pharmaceuticals Limited | Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV) |
US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4946787A (en) | 1985-01-07 | 1990-08-07 | Syntex (U.S.A.) Inc. | N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4897355A (en) | 1985-01-07 | 1990-01-30 | Syntex (U.S.A.) Inc. | N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
US4797368A (en) | 1985-03-15 | 1989-01-10 | The United States Of America As Represented By The Department Of Health And Human Services | Adeno-associated virus as eukaryotic expression vector |
US4774085A (en) | 1985-07-09 | 1988-09-27 | 501 Board of Regents, Univ. of Texas | Pharmaceutical administration systems containing a mixture of immunomodulators |
US5422251A (en) | 1986-11-26 | 1995-06-06 | Princeton University | Triple-stranded nucleic acids |
US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5176996A (en) | 1988-12-20 | 1993-01-05 | Baylor College Of Medicine | Method for making synthetic oligonucleotides which bind specifically to target sites on duplex DNA molecules, by forming a colinear triplex, the synthetic oligonucleotides and methods of use |
US5264618A (en) | 1990-04-19 | 1993-11-23 | Vical, Inc. | Cationic lipids for intracellular delivery of biologically active molecules |
WO1991017424A1 (en) | 1990-05-03 | 1991-11-14 | Vical, Inc. | Intracellular delivery of biologically active substances by means of self-assembling lipid complexes |
US5173414A (en) | 1990-10-30 | 1992-12-22 | Applied Immune Sciences, Inc. | Production of recombinant adeno-associated virus vectors |
US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US5587308A (en) | 1992-06-02 | 1996-12-24 | The United States Of America As Represented By The Department Of Health & Human Services | Modified adeno-associated virus vector capable of expression from a novel promoter |
ATE310812T1 (de) | 1994-01-18 | 2005-12-15 | Scripps Research Inst | Derivate von zinkfingerproteinen und methoden |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
ATE410518T1 (de) | 1994-03-23 | 2008-10-15 | Univ Ohio | Kompaktnukleinsäure und ihre verabreichung in zellen |
US5585245A (en) | 1994-04-22 | 1996-12-17 | California Institute Of Technology | Ubiquitin-based split protein sensor |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
ATE407205T1 (de) | 1994-08-20 | 2008-09-15 | Gendaq Ltd | Verbesserung in bezug auf bindungsproteine bei der erkennung von dna |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
US6342345B1 (en) | 1997-04-02 | 2002-01-29 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of molecular interactions by reporter subunit complementation |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
AU746454B2 (en) | 1998-03-02 | 2002-05-02 | Massachusetts Institute Of Technology | Poly zinc finger proteins with improved linkers |
CO5070700A1 (es) | 1998-06-05 | 2001-08-28 | Basf Ag | Genes novedosos de (adp-ribosa) polimerasa |
US6140815A (en) | 1998-06-17 | 2000-10-31 | Dover Instrument Corporation | High stability spin stand platform |
US6532231B1 (en) | 1998-08-29 | 2003-03-11 | Lucent Technologies Inc. | Arrangement for changing the destination of single link, single destination data messages |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
EP1147209A2 (en) | 1999-02-03 | 2001-10-24 | The Children's Medical Center Corporation | Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
CA2394850C (en) | 1999-12-06 | 2012-02-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
DE60143192D1 (de) | 2000-02-08 | 2010-11-18 | Sangamo Biosciences Inc | Zellen zur entdeckung von medikamenten |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
WO2001088197A2 (en) | 2000-05-16 | 2001-11-22 | Massachusetts Institute Of Technology | Methods and compositions for interaction trap assays |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US7067317B2 (en) | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
JP2005500061A (ja) | 2001-08-20 | 2005-01-06 | ザ スクリップス リサーチ インスティテュート | Cnnについての亜鉛フィンガー結合ドメイン |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
JP4968498B2 (ja) | 2002-01-23 | 2012-07-04 | ユニバーシティ オブ ユタ リサーチ ファウンデーション | ジンクフィンガーヌクレアーゼを用いる、標的化された染色体変異誘発 |
US20030232410A1 (en) | 2002-03-21 | 2003-12-18 | Monika Liljedahl | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
AU2003298574B2 (en) | 2002-09-05 | 2008-04-24 | California Institute Of Technology | Use of chimeric nucleases to stimulate gene targeting |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
EP2927318B1 (en) * | 2003-08-08 | 2020-05-20 | Sangamo Therapeutics, Inc. | Methods and compositions for targeted cleavage and recombination |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US7253273B2 (en) | 2004-04-08 | 2007-08-07 | Sangamo Biosciences, Inc. | Treatment of neuropathic pain with zinc finger proteins |
ATE418346T1 (de) | 2004-04-08 | 2009-01-15 | Sangamo Biosciences Inc | Zusammensetzungen zur behandlung von neuropathischen und neurodegenerativen erkrankungen |
CA2579677A1 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
CA2599004C (en) * | 2005-02-28 | 2015-05-26 | Sangamo Biosciences, Inc. | Anti-angiogenic methods and compositions |
MX2007013757A (es) | 2005-05-05 | 2008-01-24 | Univ Arizona | Reagrupacion permitida de secuencia (seer)-met odo de novedad para visualizar secuencias de adn especificas. |
EP1913149A4 (en) | 2005-07-26 | 2009-08-05 | Sangamo Biosciences Inc | TARGETED INTEGRATION AND EXPRESSION OF EXOGENOUS NUCLEIC ACID SEQUENCES |
CA3055968A1 (en) | 2005-10-18 | 2007-04-26 | Duke University | Rationally-designed meganucleases with altered sequence specificity and dna-binding affinity |
ES2378333T3 (es) | 2006-05-25 | 2012-04-11 | Sangamo Biosciences, Inc. | Métodos y composiciones para la inactivación de genes |
WO2007139898A2 (en) | 2006-05-25 | 2007-12-06 | Sangamo Biosciences, Inc. | Variant foki cleavage half-domains |
ATE489465T1 (de) | 2007-04-26 | 2010-12-15 | Sangamo Biosciences Inc | Gezielte integration in die ppp1r12c-position |
US8790345B2 (en) | 2007-08-21 | 2014-07-29 | Zimmer, Inc. | Titanium alloy with oxidized zirconium for a prosthetic implant |
AU2008305567B2 (en) | 2007-09-27 | 2014-04-10 | Sangamo Therapeutics, Inc. | Rapid in vivo identification of biologically active nucleases |
US8936936B2 (en) | 2007-10-25 | 2015-01-20 | Sangamo Biosciences, Inc. | Methods and compositions for targeted integration |
BE1018531A4 (nl) | 2007-10-31 | 2011-03-01 | Gielen Cornelis | Het gebruik van niet-pathogene bacterien in sporenvorm of in slapende vorm voor het verwijderen van huismijtuitwerpselen en organische allergieverwekkende materialen van alle soorten textiel. |
DE102007056956B4 (de) | 2007-11-27 | 2009-10-29 | Moosbauer, Peter, Dipl.-Ing.(FH) | Schaltung zur Regelung der Stromversorgung eines Verbrauchers und Verfahren zum Betrieb einer Schaltung |
JP2011518555A (ja) | 2008-04-14 | 2011-06-30 | サンガモ バイオサイエンシーズ, インコーポレイテッド | 標的組込みのための線形ドナーコンストラクト |
WO2009154686A1 (en) | 2008-05-28 | 2009-12-23 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
CA2734235C (en) | 2008-08-22 | 2019-03-26 | Sangamo Biosciences, Inc. | Methods and compositions for targeted single-stranded cleavage and targeted integration |
WO2010030963A2 (en) * | 2008-09-15 | 2010-03-18 | Children's Medical Center Corporation | Modulation of bcl11a for treatment of hemoglobinopathies |
EP3156494B8 (en) | 2008-12-04 | 2018-09-19 | Sangamo Therapeutics, Inc. | Genome editing in rats using zinc-finger nucleases |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
KR102262704B1 (ko) | 2009-08-11 | 2021-06-09 | 상가모 테라퓨틱스, 인코포레이티드 | 표적화 변형에 대한 동형접합성 유기체 |
AU2010327998B2 (en) | 2009-12-10 | 2015-11-12 | Iowa State University Research Foundation, Inc. | TAL effector-mediated DNA modification |
EP2526112B1 (en) | 2010-01-22 | 2018-10-17 | Dow AgroSciences LLC | Targeted genomic alteration |
PT2534173T (pt) | 2010-02-08 | 2019-10-31 | Sangamo Therapeutics Inc | Semidomínios de clivagem manipulados |
EP2660318A1 (en) | 2010-02-09 | 2013-11-06 | Sangamo BioSciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
WO2011139349A1 (en) | 2010-05-03 | 2011-11-10 | Sangamo Biosciences, Inc. | Compositions for linking zinc finger modules |
CA2798988C (en) | 2010-05-17 | 2020-03-10 | Sangamo Biosciences, Inc. | Tal-effector (tale) dna-binding polypeptides and uses thereof |
US20140127814A1 (en) | 2010-08-10 | 2014-05-08 | Srinivasan Chandrasegaran | Generation and use of pluripotent stem cells |
US9405700B2 (en) | 2010-11-04 | 2016-08-02 | Sonics, Inc. | Methods and apparatus for virtualization in an integrated circuit |
WO2012073047A2 (en) | 2010-12-03 | 2012-06-07 | Genome Research Limited | Compositions and methods |
KR102061557B1 (ko) | 2011-09-21 | 2020-01-03 | 상가모 테라퓨틱스, 인코포레이티드 | 이식 유전자 발현의 조절을 위한 방법 및 조성물 |
CA2852955C (en) | 2011-10-27 | 2021-02-16 | Sangamo Biosciences, Inc. | Methods and compositions for modification of the hprt locus |
BR112014020625A2 (pt) * | 2012-02-24 | 2017-07-04 | Hutchinson Fred Cancer Res | polinucleotídeo, polipeptídeo, composição, célula e célula tronco editada por genoma |
BR112014027813A2 (pt) | 2012-05-07 | 2017-08-08 | Dow Agrosciences Llc | métodos e composições para integração de transgenes direcionada mediada por nuclease |
US9873894B2 (en) | 2013-05-15 | 2018-01-23 | Sangamo Therapeutics, Inc. | Methods and compositions for treatment of a genetic condition |
-
2013
- 2013-08-29 UA UAA201501169A patent/UA118957C2/uk unknown
- 2013-08-29 EP EP13833658.1A patent/EP2890780B8/en active Active
- 2013-08-29 DK DK13833658.1T patent/DK2890780T3/da active
- 2013-08-29 PT PT138336581T patent/PT2890780T/pt unknown
- 2013-08-29 SG SG10201701601WA patent/SG10201701601WA/en unknown
- 2013-08-29 KR KR1020157004852A patent/KR102218562B1/ko active IP Right Grant
- 2013-08-29 LT LTEP13833658.1T patent/LT2890780T/lt unknown
- 2013-08-29 SG SG11201500852WA patent/SG11201500852WA/en unknown
- 2013-08-29 IN IN1480DEN2015 patent/IN2015DN01480A/en unknown
- 2013-08-29 US US14/013,250 patent/US9650648B2/en active Active
- 2013-08-29 CN CN201380045574.4A patent/CN104704110B/zh active Active
- 2013-08-29 HU HUE13833658A patent/HUE050516T2/hu unknown
- 2013-08-29 PL PL13833658T patent/PL2890780T3/pl unknown
- 2013-08-29 EA EA201590167A patent/EA039384B1/ru unknown
- 2013-08-29 US US14/013,236 patent/US9963715B2/en active Active
- 2013-08-29 RS RS20201082A patent/RS60838B1/sr unknown
- 2013-08-29 MX MX2015002409A patent/MX367081B/es active IP Right Grant
- 2013-08-29 AU AU2013308770A patent/AU2013308770B2/en active Active
- 2013-08-29 KR KR1020227041988A patent/KR20220164090A/ko not_active Application Discontinuation
- 2013-08-29 CA CA3171494A patent/CA3171494A1/en active Pending
- 2013-08-29 ES ES13833658T patent/ES2812599T3/es active Active
- 2013-08-29 JP JP2015530017A patent/JP2015533786A/ja active Pending
- 2013-08-29 WO PCT/US2013/057214 patent/WO2014036219A2/en active Application Filing
- 2013-08-29 CA CA2882499A patent/CA2882499C/en active Active
- 2013-08-29 SI SI201331781T patent/SI2890780T1/sl unknown
- 2013-08-29 KR KR1020217004409A patent/KR102474010B1/ko active IP Right Grant
-
2015
- 2015-02-02 IL IL237050A patent/IL237050B/en active IP Right Grant
- 2015-02-06 ZA ZA2015/00900A patent/ZA201500900B/en unknown
- 2015-02-25 CL CL2015000450A patent/CL2015000450A1/es unknown
- 2015-02-27 PH PH12015500433A patent/PH12015500433A1/en unknown
- 2015-11-17 HK HK15111325.6A patent/HK1210502A1/xx unknown
-
2017
- 2017-09-20 JP JP2017180131A patent/JP2017217012A/ja active Pending
-
2018
- 2018-04-02 US US15/943,082 patent/US11492643B2/en active Active
- 2018-05-15 JP JP2018093930A patent/JP6629917B2/ja active Active
-
2019
- 2019-10-04 PH PH12019502292A patent/PH12019502292A1/en unknown
-
2020
- 2020-09-10 HR HRP20201443TT patent/HRP20201443T1/hr unknown
-
2021
- 2021-10-15 JP JP2021169438A patent/JP2022001072A/ja active Pending
-
2022
- 2022-11-07 US US17/982,209 patent/US20230416775A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PH12019502292A1 (en) | Methods and compositions for treatment of a genetic condition | |
IL230836A (en) | Multi-part disinfectant system | |
EP2850184A4 (en) | COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION | |
EP2850183A4 (en) | COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION | |
RS63237B1 (sr) | Terminalno modifikovana rnk | |
IN2012DE03088A (tr) | ||
AU2013225816A8 (en) | Compositions and methods for treating Type III Gaucher Disease | |
MX2015002487A (es) | Proceso para la preparacion de teneligliptina. | |
EP2872993A4 (en) | COMPILATION OF WORKFLOW | |
SG11201407089SA (en) | Cyclosporine-containing, non-irritative nanoemulsion opthalmic composition | |
PT2708607T (pt) | Marcadores genéticos para myb28 | |
GB201206455D0 (en) | Gene expression | |
GB2505638B (en) | Continuous culture | |
GB201423420D0 (en) | Blackhoe loader | |
IN2015DN03815A (tr) | ||
EP2917534A4 (en) | DIVIDED INTERMEDIATE HOUSING | |
GB201103407D0 (en) | Genetic association | |
EP2880166A4 (en) | COMPOSITIONS AND METHODS FOR GENETIC CONSTRUCTIONS | |
GB2491544A (en) | Perpetum mobile | |
MX2012013246A (es) | Composicion supresora de polvo. | |
UA79072U (en) | (4-tert-butylperoxy-4-methylpentyl)methacrylate | |
AU348528S (en) | A food mould | |
AU338012S (en) | Dinosaur costume | |
IN2011KO00551A (tr) | ||
GB201222429D0 (en) | Nolan |